Our Mission at Artiva

Versatility. NK cells are part of the innate immune system and are the body’s natural, first line of immune surveillance and defense against tumor cells and infection. NK cells can be combined with approved therapeutic antibodies or can be engineered to potentially enhance the targeting and activity of the NK cells. Our AlloNK^TM platform includes tools designed to further modify NK cells where needed.

Safety. Unlike approved CAR-T therapy, NK cells can be used in an allogeneic, mismatched setting without induction of graft versus host disease (GVHD), potentially enabling the treatment of many patients from the same donor cells. NK cells have also not been shown to induce severe cytokine release syndrome or neurotoxicity, which are risks associated with CAR-T cell treatment.

Quality. Artiva's NK cells are generated from healthy donor umbilical cord blood (UCB) units selected for key characteristics. Our robust process yields NK cells with high purity, viability, and consistency.

Scalability. Our proprietary, large-scale, campaign-based manufacturing process is capable of producing enough pure and highly active NK cells to potentially treat hundreds to thousands of patients, with the opportunity for repeat dosing from each UCB.

Efficacy. Our NK cell therapies utilize proprietary chimeric antigen receptors (CARs), optimized for use in NK cells, and/or therapeutic antibodies to potentially enhance therapeutic activity and specificity for tumor cells.

Accessibility. Artiva's NK cells are cryopreserved and ready for off-the-shelf therapeutic use, without the requirement for manipulation at the clinical site. Our entire process is developed to achieve our goal of cost-effectiveness and to ensure broad patient access.